Quick Takeaways
- This page summarizes Christopher B. Ehrlich's Form 4 filing for eFFECTOR Therapeutics, Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Filing timestamp: 31 Jan 2022, 16:50.
Christopher B. Ehrlich - 27 Jan 2022 Form 4 Insider Report for eFFECTOR Therapeutics, Inc.
- Role
- Director
- Signature
- /s/ Michael Byrnes, Attorney-in-Fact for Christopher B. Ehrlich
- Issuer symbol
- N/A
- Transactions as of
- 27 Jan 2022
- Net transactions value
- +$26,515
- Form type
- 4
- Filing time
- 31 Jan 2022, 16:50:28 UTC
- Previous filing
- 12 Oct 2021
- Next filing
- 07 Feb 2022
- SEC
- View on sec.gov
Quoteable Key Fact
"Christopher B. Ehrlich filed Form 4 for eFFECTOR Therapeutics, Inc. on 31 Jan 2022."
What Changed
- Previous filing in this sequence was filed on 12 Oct 2021.
- Current net transaction value: +$26,515.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Source Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Transactions Table
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | EFTR | Common Stock | Purchase | $26,515 | +5,000 | $5.30 | 5,000 | 27 Jan 2022 | Direct | F1 | |
| holding | EFTR | Common Stock | 142,168 | 27 Jan 2022 | By Locust Walk Partners LLC | F2 | |||||
| holding | EFTR | Common Stock | 1,034 | 27 Jan 2022 | By Locust Walk Partners LLC | F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.23 to $5.47. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
| F2 | Represents shares held directly by the Sponsor, of which Locust Walk Partners LLC ("LWP") is a member. LWP has allocated these shares to the reporting person. |
| F3 | Represents shares held directly by the Sponsor, of which LWP is a member. LWP has allocated these shares to the reporting person's spouse. |